WO2000015790A3 - Leptin induced genes - Google Patents

Leptin induced genes Download PDF

Info

Publication number
WO2000015790A3
WO2000015790A3 PCT/US1999/020497 US9920497W WO0015790A3 WO 2000015790 A3 WO2000015790 A3 WO 2000015790A3 US 9920497 W US9920497 W US 9920497W WO 0015790 A3 WO0015790 A3 WO 0015790A3
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
proteins
induced
encoding
agents
Prior art date
Application number
PCT/US1999/020497
Other languages
French (fr)
Other versions
WO2000015790A2 (en
WO2000015790A9 (en
Inventor
David White
Jianghong Zhou
Louis A Tartaglia
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Priority to AU59114/99A priority Critical patent/AU5911499A/en
Publication of WO2000015790A2 publication Critical patent/WO2000015790A2/en
Publication of WO2000015790A9 publication Critical patent/WO2000015790A9/en
Publication of WO2000015790A3 publication Critical patent/WO2000015790A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Five genes whose expression is induced by leptin are disclosed (LIG56; Tgtp, encoding a T cell-specific GTP-binding protein; LRG-47, encoding an interferon (IFN) inducible protein; RC10-II, encoding a subunit of a 20S brain proteasome; and Stra13, encoding a retinoic acid inducible protein). These five leptin-inducible genes and the proteins they encode represent targets for the development of therapeutic agents for use in modulating body weight. For example, agents that alter the expression or activity of one or more of the leptin-induced proteins can be used to modulate body weight. Such agents can be identified using cellular, in vitro, or in vivo assays which monitor the expression or activity of one or more of the six leptin-induced proteins. Potentially useful therapeutic agents can also be identified through the use of assays designed to identify agents that bind to one of the leptin-induced proteins. The leptin-induced genes of the invention and the proteins they encode may themselves be useful therapeutically and diagnostically.
PCT/US1999/020497 1998-09-10 1999-09-10 Leptin induced genes WO2000015790A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59114/99A AU5911499A (en) 1998-09-10 1999-09-10 Leptin induced genes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15085798A 1998-09-10 1998-09-10
US09/150,857 1998-09-10
US10637898P 1998-10-29 1998-10-29
US60/106,378 1998-10-29
US19589698A 1998-11-19 1998-11-19
US09/195,896 1998-11-19
US29222899A 1999-04-15 1999-04-15
US09/292,228 1999-04-15

Publications (3)

Publication Number Publication Date
WO2000015790A2 WO2000015790A2 (en) 2000-03-23
WO2000015790A9 WO2000015790A9 (en) 2000-10-12
WO2000015790A3 true WO2000015790A3 (en) 2000-11-23

Family

ID=27493515

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/020722 WO2000015826A2 (en) 1998-09-10 1999-09-10 Leptin induced genes
PCT/US1999/020497 WO2000015790A2 (en) 1998-09-10 1999-09-10 Leptin induced genes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020722 WO2000015826A2 (en) 1998-09-10 1999-09-10 Leptin induced genes

Country Status (9)

Country Link
US (1) US20020119517A1 (en)
EP (1) EP1109908B1 (en)
JP (1) JP2002525067A (en)
AT (1) ATE302274T1 (en)
AU (2) AU6031899A (en)
CA (1) CA2342965A1 (en)
DE (1) DE69926764T2 (en)
MX (1) MXPA01002461A (en)
WO (2) WO2000015826A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4551041B2 (en) 1999-06-29 2010-09-22 協和発酵キリン株式会社 Useful polypeptides
AU2001297567A1 (en) * 2000-11-21 2002-10-03 Millennium Pharmaceuticals, Inc. Leptin induced genes
JPWO2002101034A1 (en) * 2001-06-08 2004-09-24 ゾイジーン株式会社 Leptin-inducible gene
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
TW200518768A (en) * 2003-11-17 2005-06-16 Pepgen Corp Methods for treatment of obesity and for promotion of weight loss
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN102264228A (en) 2008-10-22 2011-11-30 默沙东公司 Novel cyclic benzimidazole derivatives useful for anti-diabetic agents
JP5557845B2 (en) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103476258B (en) 2011-02-25 2017-04-26 默沙东公司 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (en) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. ANTI-DIABETIC BICYCLIC COMPOUNDS
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHOU ET AL.: "Induction by leptin of uncoupling protein 2 and enzyes o fatty acid oxidation", PROC. NATL. ACAD. SCI. USA, vol. 94, June 1997 (1997-06-01), pages 6386 - 6390, XP002137954 *

Also Published As

Publication number Publication date
JP2002525067A (en) 2002-08-13
WO2000015826A2 (en) 2000-03-23
MXPA01002461A (en) 2003-03-10
AU5911499A (en) 2000-04-03
WO2000015826A3 (en) 2000-11-09
EP1109908A2 (en) 2001-06-27
WO2000015790A2 (en) 2000-03-23
AU6031899A (en) 2000-04-03
DE69926764D1 (en) 2005-09-22
DE69926764T2 (en) 2006-06-29
US20020119517A1 (en) 2002-08-29
WO2000015790A9 (en) 2000-10-12
ATE302274T1 (en) 2005-09-15
CA2342965A1 (en) 2000-03-23
EP1109908B1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
WO2000015790A3 (en) Leptin induced genes
HUP0003533A2 (en) Interleukin-18 binding proteins, their preparation and use
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
WO1996034953A3 (en) Cd16-ii variants
HUP9902429A2 (en) Modulators of tnf receptor associated factor (traf), their preparation and use
DK0643726T3 (en) Human p53 protein peptides for use in compositions that induce human T cell response and human p53 protein
DK0836485T3 (en) Cascade-polymer complexes, processes for their preparation, and pharmaceutical agents containing them
ES2161246T3 (en) TRANSFORMING FACTOR OF ALFA H1 GROWTH.
DE68929043T2 (en) DNA ENCODING ANDROGEN RECEPTOR PROTEIN
Pillion et al. Identification of insulin receptors on the mucosal surface of colon epithelial cells.
BR9816013A (en) Interleukin-18 Binding Protein
MXPA02008239A (en) Human schizophrenia gene.
HUP9802961A2 (en) Binding partners for cyclin-dependent kinase-inhibitors, use thereof for exploring of inhibitors of deseases, for diagnostic and therapy
AU9363398A (en) Hepatitis c receptor protein cd81
FR2724320B1 (en) NEW IMPLANT FOR THE TREATMENT OF ACQUIRED DISEASES
WO2001064876A3 (en) Human schizophrenia gene
AP2368A (en) Novel expression vectors and uses thereof.
HUP0001057A2 (en) Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation
DK0941341T3 (en) Nucleotide sequence encoding a flavin monooxygenase, the corresponding protein and their applications in diagnostics and therapy
NO962596L (en) New tumor suppressor gene
EP0780472A3 (en) Stress proteins
DE69712182T2 (en) PEPTIDES AND THEIR USE IN THE THERAPY OF DISEASES OF THE CELEBIA FORM
HUP9702147A2 (en) Human dnase i variants
DE69529235T2 (en) HUMAN DNASE I VARIANTS
HUP0001184A2 (en) Polypeptides of the "basic-helix-loop-helix" bhlh family, corresponding nucleic acid sequences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase